Altimmune (NASDAQ:ALT) Now Covered by Stifel Nicolaus

Stifel Nicolaus assumed coverage on shares of Altimmune (NASDAQ:ALT - Get Free Report) in a research report issued on Wednesday, MarketBeat reports. The firm set a "buy" rating and a $18.00 price target on the stock. Stifel Nicolaus' price target indicates a potential upside of 141.61% from the company's previous close.

Several other brokerages have also recently commented on ALT. HC Wainwright reiterated a "buy" rating and set a $12.00 target price on shares of Altimmune in a research report on Thursday, November 14th. UBS Group began coverage on Altimmune in a report on Tuesday, November 12th. They issued a "buy" rating and a $26.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Altimmune presently has an average rating of "Moderate Buy" and an average price target of $19.71.

Altimmune Price Performance

Shares of ALT stock traded up $0.14 during trading hours on Wednesday, hitting $7.45. 2,743,019 shares of the company's stock were exchanged, compared to its average volume of 2,582,943. The stock's 50-day moving average is $8.08 and its 200-day moving average is $7.20. Altimmune has a 52 week low of $5.28 and a 52 week high of $14.84. The stock has a market cap of $529.88 million, a price-to-earnings ratio of -4.81 and a beta of 0.22.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.03. The firm had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the previous year, the business posted ($0.39) EPS. Equities research analysts forecast that Altimmune will post -1.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Altimmune

A number of hedge funds and other institutional investors have recently made changes to their positions in ALT. Geode Capital Management LLC raised its holdings in shares of Altimmune by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company's stock valued at $10,244,000 after purchasing an additional 74,194 shares during the last quarter. Bellevue Group AG boosted its stake in shares of Altimmune by 43.9% during the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company's stock worth $5,303,000 after buying an additional 263,660 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Altimmune by 142.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company's stock valued at $3,791,000 after acquiring an additional 335,444 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Altimmune by 28.6% in the second quarter. Bank of New York Mellon Corp now owns 243,808 shares of the company's stock valued at $1,621,000 after acquiring an additional 54,154 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its position in Altimmune by 74.4% during the third quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company's stock valued at $1,331,000 after purchasing an additional 92,498 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.